A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

AJ (Diane) van der Biessen; JA Gietema; Maja de Jonge; IME Desar; M W den Hollander; M Dudley; M Dunbar; R Hetman; C Serpenti; H (Hong) Xiong; RK Mittapalli; KM Timms; P Ansell; CK Ratajczak; SP Shepherd; CML van Herpen

doi:10.1007/s10637-017-0551-z

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

AJ (Diane) van der Biessen, JA Gietema, Maja de Jonge, IME Desar, M W den Hollander, M Dudley, M Dunbar, R Hetman, C Serpenti, H (Hong) Xiong, RK Mittapalli, KM Timms, P Ansell, CK Ratajczak, SP Shepherd, CML van Herpen

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Scopus)

6 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	828-835
Number of pages	8
Journal	Investigational New Drugs
Volume	36
Issue number	5
DOIs	https://doi.org/10.1007/s10637-017-0551-z
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10637-017-0551-z

Repub-110337-OA.pdfFinal published version, 0 bytes

http://hdl.handle.net/1765/110337

Cite this

van der Biessen, AJ., Gietema, JA., de Jonge, M., Desar, IME., den Hollander, M. W., Dudley, M., Dunbar, M., Hetman, R., Serpenti, C., Xiong, H., Mittapalli, RK., Timms, KM., Ansell, P., Ratajczak, CK., Shepherd, SP., & van Herpen, CML. (2018). A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Investigational New Drugs, 36(5), 828-835. https://doi.org/10.1007/s10637-017-0551-z

@article{b2576cf1380c422cb2308fd8d120f780,

title = "A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer",

author = "{van der Biessen}, {AJ (Diane)} and JA Gietema and {de Jonge}, Maja and IME Desar and {den Hollander}, {M W} and M Dudley and M Dunbar and R Hetman and C Serpenti and Xiong, {H (Hong)} and RK Mittapalli and KM Timms and P Ansell and CK Ratajczak and SP Shepherd and {van Herpen}, CML",

year = "2018",

doi = "10.1007/s10637-017-0551-z",

language = "Undefined/Unknown",

volume = "36",

pages = "828--835",

journal = "Investigational New Drugs",

issn = "0167-6997",

number = "5",

}

van der Biessen, AJ, Gietema, JA, de Jonge, M, Desar, IME, den Hollander, MW, Dudley, M, Dunbar, M, Hetman, R, Serpenti, C, Xiong, H, Mittapalli, RK, Timms, KM, Ansell, P, Ratajczak, CK, Shepherd, SP & van Herpen, CML 2018, 'A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer', Investigational New Drugs, vol. 36, no. 5, pp. 828-835. https://doi.org/10.1007/s10637-017-0551-z

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. / van der Biessen, AJ (Diane); Gietema, JA; de Jonge, Maja et al.
In: Investigational New Drugs, Vol. 36, No. 5, 2018, p. 828-835.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

AU - van der Biessen, AJ (Diane)

AU - Gietema, JA

AU - de Jonge, Maja

AU - Desar, IME

AU - den Hollander, M W

AU - Dudley, M

AU - Dunbar, M

AU - Hetman, R

AU - Serpenti, C

AU - Xiong, H (Hong)

AU - Mittapalli, RK

AU - Timms, KM

AU - Ansell, P

AU - Ratajczak, CK

AU - Shepherd, SP

AU - van Herpen, CML

PY - 2018

Y1 - 2018

U2 - 10.1007/s10637-017-0551-z

DO - 10.1007/s10637-017-0551-z

M3 - Article

SN - 0167-6997

VL - 36

SP - 828

EP - 835

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 5

ER -